For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
The advent of stem cell technologies has opened up new opportunities in drug discovery and development by providing new tools for drug screening, target identification, and toxicity testing. The discovery of reprogramming patient-derived somatic cells into induced pluripotent stem cells (iPSCs) has offered a promising alternative to generate many human cell types but rarely at the scale, consistency and cost point required for HTS.
Although iPSC-derived neurons have promising applications in drug discovery platforms, their use within HTS has previously been limited by traditional ‘directed differentiation’ approaches, making it difficult to generate reliable, homogenous cell populations at scale. Novel iPSC-derived ioNEURONS/glut, generated using opti-ox reprogramming technology, overcome these restrictions to provide a robust platform for drug discovery.
Download the Charles River poster to find out more about how human iPSC-derived ioNEURONS/glut cells are overcoming these limitations.
Download the poster presented by Charles River at SfN for more information on how human iPSC-derived ioNEURONS/glut were generated using opti-ox cellular reprogramming, and subsequently molecularly and functionally characterized.